Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 48

1.

Avahan and the cost-effectiveness of "prevention as prevention".

Marseille E, Kahn JG.

Lancet Glob Health. 2014 Sep;2(9):e493-4. doi: 10.1016/S2214-109X(14)70295-5. Epub 2014 Aug 27. No abstract available.

2.

Global cost-effectiveness of GDM screening and management: Current knowledge and future needs.

Weile LK, Kahn JG, Marseille E, Jensen DM, Damm P, Lohse N.

Best Pract Res Clin Obstet Gynaecol. 2015 Feb;29(2):206-24. doi: 10.1016/j.bpobgyn.2014.06.009. Epub 2014 Aug 21.

PMID:
25225056
3.

Essential surgery is cost effective in resource-poor countries.

Marseille E, Morshed S.

Lancet Glob Health. 2014 Jun;2(6):e302-3. doi: 10.1016/S2214-109X(14)70236-0. Epub 2014 May 21. No abstract available.

4.

Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries.

Marseille E, Jiwani A, Raut A, Verguet S, Walson J, Kahn JG.

BMJ Open. 2014 Jun 26;4(6):e003987. doi: 10.1136/bmjopen-2013-003987.

5.

Estimating the cost-effectiveness of nutrition supplementation for malnourished, HIV-infected adults starting antiretroviral therapy in a resource-constrained setting.

Koethe JR, Marseille E, Giganti MJ, Chi BH, Heimburger D, Stringer JS.

Cost Eff Resour Alloc. 2014 Apr 27;12:10. doi: 10.1186/1478-7547-12-10. eCollection 2014.

6.

Integrated disease prevention campaigns: assessing country opportunity for implementation via an index approach.

Jiwani A, Matheson A, Kahn JG, Raut A, Verguet S, Marseille E, Walson J.

BMJ Open. 2014 Mar 19;4(3):e004308. doi: 10.1136/bmjopen-2013-004308.

7.

Adult male circumcision in Nyanza, Kenya at scale: the cost and efficiency of alternative service delivery modes.

Marseille E, Kahn JG, Beatty S, Jared M, Perchal P.

BMC Health Serv Res. 2014 Jan 23;14:31. doi: 10.1186/1472-6963-14-31.

8.

Capsule commentary on Long and Stavert, portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis.

Kahn JG, Marseille EA.

J Gen Intern Med. 2013 Oct;28(10):1350. doi: 10.1007/s11606-013-2519-9. No abstract available.

9.

Viral load monitoring for antiretroviral therapy in resource-poor settings: an evolving role.

Kahn JG, Marseille EA.

AIDS. 2013 Jun 1;27(9):1509-11. doi: 10.1097/QAD.0b013e3283617544. No abstract available.

PMID:
23759750
10.

Cost-effectiveness analyses of training: a manager's guide.

O'Malley G, Marseille E, Weaver MR.

Hum Resour Health. 2013 May 20;11:20. doi: 10.1186/1478-4491-11-20.

11.

The cost-effectiveness of gestational diabetes screening including prevention of type 2 diabetes: application of a new model in India and Israel.

Marseille E, Lohse N, Jiwani A, Hod M, Seshiah V, Yajnik CS, Arora GP, Balaji V, Henriksen O, Lieberman N, Chen R, Damm P, Metzger BE, Kahn JG.

J Matern Fetal Neonatal Med. 2013 May;26(8):802-10. doi: 10.3109/14767058.2013.765845. Epub 2013 Feb 14.

PMID:
23311860
12.

Taking ART to scale: determinants of the cost and cost-effectiveness of antiretroviral therapy in 45 clinical sites in Zambia.

Marseille E, Giganti MJ, Mwango A, Chisembele-Taylor A, Mulenga L, Over M, Kahn JG, Stringer JS.

PLoS One. 2012;7(12):e51993. doi: 10.1371/journal.pone.0051993. Epub 2012 Dec 20.

13.

Case management to improve adherence for HIV-infected patients receiving antiretroviral therapy in Ethiopia: a micro-costing study.

Marseille EA, Kevany S, Ahmed I, Feleke G, Graham B, Heller T, Kahn JG, Reyes M.

Cost Eff Resour Alloc. 2011 Dec 20;9:18. doi: 10.1186/1478-7547-9-18.

14.

Development of a model to assess the cost-effectiveness of gestational diabetes mellitus screening and lifestyle change for the prevention of type 2 diabetes mellitus.

Lohse N, Marseille E, Kahn JG.

Int J Gynaecol Obstet. 2011 Nov;115 Suppl 1:S20-5. doi: 10.1016/S0020-7292(11)60007-6.

PMID:
22099435
15.

CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study.

Kahn JG, Marseille E, Moore D, Bunnell R, Were W, Degerman R, Tappero JW, Ekwaru P, Kaharuza F, Mermin J.

BMJ. 2011 Nov 9;343:d6884. doi: 10.1136/bmj.d6884.

16.

Cost-effectiveness of antiretroviral therapy for prevention.

Kahn JG, Marseille EA, Bennett R, Williams BG, Granich R.

Curr HIV Res. 2011 Sep;9(6):405-15. Review.

17.

Gestational diabetes mellitus: results from a survey of country prevalence and practices.

Jiwani A, Marseille E, Lohse N, Damm P, Hod M, Kahn JG.

J Matern Fetal Neonatal Med. 2012 Jun;25(6):600-10. doi: 10.3109/14767058.2011.587921. Epub 2011 Jul 15.

PMID:
21762003
18.

The cost-effectiveness of HIV prevention interventions for HIV-infected patients seen in clinical settings.

Marseille E, Shade SB, Myers J, Morin S.

J Acquir Immune Defic Syndr. 2011 Mar 1;56(3):e87-94. doi: 10.1097/QAI.0b013e318204123e.

PMID:
21317579
19.

The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda.

Marseille E, Kahn JG, Pitter C, Bunnell R, Epalatai W, Jawe E, Were W, Mermin J.

Appl Health Econ Health Policy. 2009;7(4):229-43. doi: 10.2165/11318740-000000000-00000.

20.

Estimating the resources needed and savings anticipated from roll-out of adult male circumcision in Sub-Saharan Africa.

Auvert B, Marseille E, Korenromp EL, Lloyd-Smith J, Sitta R, Taljaard D, Pretorius C, Williams B, Kahn JG.

PLoS One. 2008 Aug 6;3(8):e2679. doi: 10.1371/journal.pone.0002679.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk